Open in interactive viewer → charts, metric popovers & call review

Cellebrite Grew 20% and Quietly Lowered the Ceiling Anyway

The beat was real; the story is that Genesis became a platform, Corellium became a problem, and federal stopped being the excuse
CLBT · Earnings Call · 2026-11-12

The bounce, and the asterisk attached to it

Cellebrite's third quarter was the operational recovery management promised after a bruising Q2. ARR grew 20% to $528.5 million, above the high end of guidance; revenue rose 18% to $149 million; adjusted EBITDA jumped 42% to $53.6 million and free cash flow hit $52 million in the quarter, a 31% trailing margin. On any single line, this is a beat. But look at what came with it. The company reaffirmed its full-year ARR range of $550–560 million while explicitly steering the market to the bottom of it — “We have higher confidence in the lower end of this range at present, given the traditional seasonality of our business, the volume of expiring agreements, and the uncertain timing of larger, more complex deals involving cloud and AI.” — David Barter, Chief Financial Officer · 2026-11-12 And it fine-tuned the revenue outlook to $553–558 million (16%–17% growth), a trim it blamed on the ongoing adoption of cloud and AI solutions, which are recognized ratably. That is the real theme of this print: a company whose growth is migrating from chunky, recognizable hardware and term licenses into smoother, slower-burning subscription and consumption. CFO David Barter was candid that the mix is not cooperating with tidy modeling. The hardware and non-recurring line has floated between $10 million and $14 million a quarter, and it is drifting. “I wish it were more just a straight linear journey. It's not. As deals are coming in, and quite frankly, deals are coming in with more cloud and more AI, it's just ratabilizing more of the revenue.” — David Barter, Chief Financial Officer · 2026-11-12 The hardware wobble is now a structural feature of the model, not a one-quarter blip — and Barter signaled he will eventually add MongoDB-style disclosure to split term-license from ratable revenue so investors can track it.

Genesis: the launch that becomes a platform

Genesis, the purpose-built agentic investigative product, closed its first full quarter at $2 million of ARR — the “strongest start of any product we have ever launched.” — David Barter, Chief Financial Officer · 2026-11-12 Perhaps the sharpest datapoint: Genesis was not in any customer's annual budget this year, so the deals won reflect agencies reprioritizing spend to fund it. That is genuine pull, not a sales push. It is what happens next that changes the story. Genesis is being re-cast from a product into a platform — Genesis platform now sits near the top of the company's momentum table, and management is explicit that in 2027 it becomes the delivery vehicle for the entire portfolio, priced in tiers with consumption on top. An on-premise, air gapped version ships before year-end, aimed squarely at defense and intelligence customers with policy constraints against cloud.

In 2027, Genesis will evolve from a purpose-built agentic AI product into an AI-native platform that will collect digital evidence from devices, cloud services, and other sources, securely share and analyze vast volumes of relevant artifacts, facilitate mission-critical workflows, and rapidly deliver trusted, court-ready insight.

Shiven Ramji, Chief Executive Officer · 2026-11-12
Contrast that with the Genesis rhetoric six months ago. In May, then-CEO Tom Hogan framed the product as a land-grab with deliberately underpriced distribution: “We're going to err out of the gate on being aggressive with pricing because our goal is to get this distributed broadly across the entire — we believe that once anybody touches this product, they will never give it up.” — Thomas Hogan, CEO · 2026-05-14 He sketched a $12.5 billion TAM and a $600 million revenue ambition. Today the language is more disciplined: a "surety" meter, a "hover and spend" function, and an admission from CRO Marcus Jewell that pure token-burn pricing simply cannot pass a U.S. public-sector procurement process. The product is real; the go-to-market is maturing into something procurement-ready rather than hype-ready. On the broad market, this is a verticalized slice of a genuinely global current: Personal AI agents sits inside the market-wide top-20 themes this quarter, and agentic workflows are showing up across a wide spread of recent reporters. Cellebrite is not inventing the agent wave — it is applying it to a niche with chain-of-custody requirements that generic LLMs cannot meet.

Corellium and the foreign-filer bill coming due

The acquisition that was once a growth engine is now the drag. Corellium — a keyword that spiked to the top of the company's momentum table when the deal closed — has flipped into a decliner, and management owned it plainly: “Nevertheless, we were disappointed by limited new sales and higher-than-expected churn for Corellium.” — Shiven Ramji, Chief Executive Officer · 2026-11-12 The explanation is the same foreign-entity problem that wrecked Q2, laid bare in August when Jewell described a compliance permit that blindsided the sales organization: “Since learning that and learning that process, which created a 4- to 5-week delay, we've managed to secure a master FEP, which means that at a departmental level now, we will be much more expedited in the processing of our orders.” — Marcus Jewell, Chief Revenue Officer · 2026-08-13 That was a promise. Q3 is where it gets cashed in — the redomiciliation to the United States, targeted for the first half of 2027, is the structural fix: it removes the foreign filer stigma, opens index eligibility, and, per management, was already rescuing customer conversations. It is also the single biggest reason to believe the Q2 air-pocket was a process failure rather than a demand failure.

What stopped being said

The quietest signal is in what management de-emphasized. U.S. federal remains the number-one keyword, and the business genuinely reaccelerated to 18% growth from mid-teens. But the broader "Federal business" phrase has slid into the company's decliner list this quarter. For six straight quarters, federal was the rescue story investors waited on; now it is a base business that is simply working, while the narrative oxygen has moved to Genesis. That is a healthy hand-off — if Genesis delivers. The other thing being quietly deflated is the conversion engine. Inseyets conversion climbed from roughly 65% to 75% of the install base, but the CFO pre-emptively capped expectations on the remainder: the last tranche will produce a lighter uplift and fewer expansions than the prior two years, and that assumption is now baked into guidance. This is the honest unwinding of a multi-quarter story that first cracked in Q2. Underneath it all is the ROI argument that actually sells the product — and it is not technology, it is labor. “Cold cases tend to be very expensive to run with humans. Running them with AI is a big backlog clearer.” — Marcus Jewell, Chief Revenue Officer · 2026-11-12 Jewell ties the pitch to police overtime budgets: if an agentic layer keeps an investigator off-site, chiefs fund it from savings rather than new money. That is the most durable part of the Genesis thesis — it explains why $2 million of ARR arrived without a budget line. The verdict. Cellebrite is a ~$3.2 billion market-cap software company whose stock has been halved on the subscription transition it is now embracing. This report does not resolve that tension — it reframes it. The beat was real, but the guide was trimmed at the top, the growth engine was renamed a platform, the acquisition was written down in tone, and the conversion story was capped. What changed at this company is not the quarter. It is that management has stopped selling the future in billions and started describing the plumbing required to get there.